Neuroprotective approaches in experimental models of beta-amyloid neurotoxicity: relevance to Alzheimer's disease.
about
Characterization of intermolecular beta-sheet peptides by mass spectrometry and hydrogen isotope exchange.NMDA-mediated Ca(2+) influx drives aberrant ryanodine receptor activation in dendrites of young Alzheimer's disease mice.Neuroprotection by the synthetic neurosteroid enantiomers ent-PREGS and ent-DHEAS against Aβ₂₅₋₃₅ peptide-induced toxicity in vitro and in vivo in miceReducing mitochondrial decay with mitochondrial nutrients to delay and treat cognitive dysfunction, Alzheimer's disease, and Parkinson's disease.Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseasesAlzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits.Enhanced toxicity and cellular binding of a modified amyloid beta peptide with a methionine to valine substitution.Amyloid beta peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A2 in cortical neurons.Cyclooxygenase (COX)-1 activity precedes the COX-2 induction in Aβ-induced neuroinflammation.La lunga attesa: towards a molecular approach to neuroimaging and therapeutics in Alzheimer's disease.Beta-amyloid treatment sensitizes mice to amphetamine-induced locomotion but reduces response to caffeine.A case for a non-transgenic animal model of Alzheimer's disease.2-Phenylethynyl-butyltellurium attenuates amyloid-β peptide(25-35)-induced learning and memory impairments in mice.Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits.
P2860
Q30882523-85D3D7C9-1AD5-4488-8B74-D44A997CB504Q34149384-8A2C591A-6DB1-4570-B04C-71F0CA55A7C0Q34300822-DB48A298-18F3-47A5-969B-01F380F969B6Q36212135-1B3F2307-0E0C-4AAC-A4B8-1FCD69E87671Q38168475-DF0F927A-3C7E-472F-A4A2-2BDC167EB08FQ43556693-15EEBB32-7A5B-457C-8BB8-14197B1C7A47Q45005831-8B2FA709-776C-4827-AB20-BB4D999AFF46Q46697248-A834AFE1-42EE-4D2D-B0C1-DEC97B1C4D5EQ46836622-C816CAB6-B3E4-4522-9933-F27A344D68F7Q48396205-741A51A0-548E-4B9A-8AB4-5EEE10FF7619Q48447181-BEAB0DC2-76F1-43C4-8342-6897E0AF1DE2Q48943001-80652394-E85A-4944-81D2-2CB1F016D411Q50750285-74A5FB9B-22EC-4B7E-B348-74BD8223FF51Q51409146-7163CF9C-3F3D-43FA-AA09-4CB67CD6DE88
P2860
Neuroprotective approaches in experimental models of beta-amyloid neurotoxicity: relevance to Alzheimer's disease.
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Neuroprotective approaches in ...... evance to Alzheimer's disease.
@ast
Neuroprotective approaches in ...... evance to Alzheimer's disease.
@en
type
label
Neuroprotective approaches in ...... evance to Alzheimer's disease.
@ast
Neuroprotective approaches in ...... evance to Alzheimer's disease.
@en
prefLabel
Neuroprotective approaches in ...... evance to Alzheimer's disease.
@ast
Neuroprotective approaches in ...... evance to Alzheimer's disease.
@en
P2093
P1476
Neuroprotective approaches in ...... evance to Alzheimer's disease.
@en
P2093
Hortobágyi T
P304
P356
10.1016/S0278-5846(99)00058-5
P577
1999-08-01T00:00:00Z